FDA Determines Regulatory Review Period for SAPIEN XT TRANSCATHETER HEART VALVE

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the SAPIEN XT TRANSCATHETER HEART VALVE, as required by law, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO)